Tag: NSCLC,Press Releases,VeriStrat decision impact,lung cancer,palliative care
-
New Study Shows Biodesix’s VeriStrat Changes Treatment Decisions for Lung Cancer Patients; Reduces Over-Treatment at End of Life
Biodesix®, Inc. announced today the results of a study demonstrating that the use of the VeriStrat® test for patients with non-small cell lung cancer (NSCLC) directly impacts physician treatment decisions in real-world clinical practice. In the study, use of the VeriStrat test resulted in an 89% decrease in ineffective treatments for patients who tested VeriStrat-Poor.…